Annaida Technologies SA Company
Annaida Technologies SA has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance at a scale 10-fold better than existing technologies, enabling non invasive chemical analysis at the scale of a single human embryo. Nuclear opens new global markets in assisted reproductive technology (“ART”), enabling non-invasive embryo viability screening for in vitro fertilization (“IVF”), as well as in biochemical research.
(Reupload).png)
Industry:
Reproductive Health & Contraception
Headquarters:
Lausanne, Vaud, Switzerland
Founded Date:
06-08-2018
Employees Number:
1-10
Funding Status:
Seed
Investors Number:
9
Total Funding:
$1,487,439
Last Funding Date:
2020-04-09
Last Funding Type:
Seed
Register and Claim Ownership